NCT03362164 Evaluation of HEArt invoLvement in Patients With FABRY Disease
| NCT ID | NCT03362164 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wuerzburg University Hospital |
| Condition | Rare Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 650 participants |
| Start Date | 2001-01 |
| Primary Completion | 2032-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 650 participants in total. It began in 2001-01 with a primary completion date of 2032-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
Eligibility Criteria
Inclusion Criteria: * Fabry disease (genetically confirmed) * Signed informed consent * 18 years and older Exclusion Criteria: * No informed consent * Withdrawal of informed consent
Contact & Investigator
Peter Nordbeck, MD, PhD
PRINCIPAL INVESTIGATOR
Wuerzburg University Hospital
Frequently Asked Questions
Who can join the NCT03362164 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rare Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03362164 currently recruiting?
Yes, NCT03362164 is actively recruiting participants. Contact the research team at nordbeck_p@ukw.de for enrollment information.
Where is the NCT03362164 trial being conducted?
This trial is being conducted at Würzburg, Germany.
Who is sponsoring the NCT03362164 clinical trial?
NCT03362164 is sponsored by Wuerzburg University Hospital. The principal investigator is Peter Nordbeck, MD, PhD at Wuerzburg University Hospital. The trial plans to enroll 650 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.